(1S)-1-[((3R,4R)-2,5-Dioxo-3,4-dibenzoyloxypyrrolidinyl)-oxycarbonyloxy]-2-methylpropyl 2-methylpropanoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1S)-1-[((3R,4R)-2,5-Dioxo-3,4-dibenzoyloxypyrrolidinyl)-oxycarbonyloxy]-2-methylpropyl 2-methylpropanoate
• 英文别名: (1S)-1-[((3R,4R)-2,5-dioxo-3,4-dibenzoyloxypyrrolidinyl)oxycarbonyloxy]-2-methylpropyl 2-methylpropanoate；[(3R,4R)-4-benzoyloxy-1-[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonyloxy-2,5-dioxopyrrolidin-3-yl] benzoate
• 化学式: C₂₇H₂₇NO₁₁
• 分子量: 541.511
• InChiKey: ZBJUFRRUYKKMMM-KYTVRQNUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  39
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  152
• 氢给体数：
  0
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  (1S)-1-[((3R,4R)-2,5-Dioxo-3,4-dibenzoyloxypyrrolidinyl)-oxycarbonyloxy]-2-methylpropyl 2-methylpropanoate 、 (R)-巴氯芬 在 (R)-巴氯芬 作用下， 以>99% de; 90的产率得到(ΒR)-4-氯-Β-[[[[(1S)-2-甲基-1-(2-甲基-1-氧代丙氧基)丙氧基]羰基]氨基]甲基]-苯丙酸
  参考文献：
  名称：

  USE OF (3R)-4--3-(4-CHLOROPHENYL) BUTANOIC ACID FOR TREATING URINARY INCONTINENCE

  摘要：

  公开了使用(3R)-4-{[(1S)-2-甲基-1-(2-甲基丙酰氧基)丙氧基]羰基氨基}-3-(4-氯苯基)丁酸治疗尿失禁的方法。

  公开号：

  US20110212984A1
• 作为产物：
  描述：

  isopropyl-(methylthiocarbonyloxy)methyl 2-methylpropionate 、 (+)-二苄氧基-L-酒石酸酐 在 过氧乙酸 作用下， 以 溶剂黄146 、 1,2-二氯乙烷 为溶剂， 反应 14.0h， 以25%的产率得到(1S)-1-[((3R,4R)-2,5-Dioxo-3,4-dibenzoyloxypyrrolidinyl)-oxycarbonyloxy]-2-methylpropyl 2-methylpropanoate
  参考文献：
  名称：

  [EN] SYNTHESIS OF ACYLOXYALKYL CARBAMATE PRODRUGS AND INTERMEDIATES THEREOF
  [FR] SYNTHESE DE PROMEDICAMENTS A BASE DE CARBAMATE D'ACYLOXYALKYLE ET LEURS INTERMEDIAIRES

  摘要：

  公开号：

  WO2005066122A3

文献信息

• Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
  申请人：Gallop A. Mark

  公开号：US20060111325A1

  公开（公告）日：2006-05-25

  Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of making prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of using prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and pharmaceutical compositions thereof for treating or preventing diseases or disorders such as spasticity or gastroesophageal reflux disease are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and sustained release oral dosage forms thereof, which are suitable for oral administration, are also disclosed.

  3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的酰氧烷基氨基甲酸酯前药，包括3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的酰氧烷基氨基甲酸酯前药的药物组合物，制备3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的前药的方法，使用3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的前药的方法，以及用于治疗或预防痉挛或胃食管反流病等疾病或紊乱的药物组合物。还公开了适用于口服的酰氧烷基氨基甲酸酯前药、3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的持续释放口服剂型。
• Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
  申请人：Gallop A. Mark

  公开号：US20060111439A1

  公开（公告）日：2006-05-25

  Acyloxyalkyl carbamate prodrugs of 3-aminopropylsulfinic acid and analogs thereof, pharmaceutical compositions of 3-aminopropylsulfinic acid and analogs thereof, methods of making prodrugs of 3-aminopropylsulfinic acid and analogs thereof, methods of using prodrugs of 3-aminopropylsulfinic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing diseases or disorders such as spasticity or gastroesophageal reflux disease are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylsulfinic acid and analogs thereof and sustained release oral dosage forms thereof, which are suitable for oral administration, are also disclosed.

  3-氨基丙磺酸及其类似物的酰氧烷基氨基甲酸酯前药，3-氨基丙磺酸及其类似物的药物组合物，制备3-氨基丙磺酸及其类似物的前药的方法，使用3-氨基丙磺酸及其类似物的前药的方法，以及用于治疗或预防痉挛性或胃食管反流病等疾病或紊乱的药物组合物已被披露。此外，还披露了适用于口服的3-氨基丙磺酸及其类似物的酰氧烷基氨基甲酸酯前药和持续释放口服剂型。
• MESOPHASIC FORMS OF (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACID PRODRUGS AND METHODS OF USE
  申请人：Yao Fenmei

  公开号：US20090192222A1

  公开（公告）日：2009-07-30

  Mesophasic forms of (3S)-aminomethyl-5-hexanoic acid prodrugs and methods of preparing and methods of using mesophasic forms of (3S)-aminomethyl-5-hexanoic acid prodrugs are provided.

  本发明提供了(3S)-氨甲基-5-己酸前药的介相形式及其制备方法和使用方法。
• Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
  申请人：Gallop A. Mark

  公开号：US20050107334A1

  公开（公告）日：2005-05-19

  The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.

  本文涉及的内容通常与(±)-4-氨基-3-(4-氯苯基)丁酸及其类似物的酰氧基烷基氨基甲酸酯前药、其制药组合物、制备(±)-4-氨基-3-(4-氯苯基)丁酸及其类似物的前药的方法、使用(±)-4-氨基-3-(4-氯苯基)丁酸及其类似物的前药的方法，以及治疗或预防常见疾病和/或疾病，如痉挛和/或酸反流病的制药组合物。本文还涉及适用于口服和口服缓释剂型的(±)-4-氨基-3-(4-氯苯基)丁酸及其类似物的酰氧基烷基氨基甲酸酯前药。
• Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
  申请人：Gallop A. Mark

  公开号：US20050222431A1

  公开（公告）日：2005-10-06

  Methods for synthesis of 1 -(acyloxy)-alkyl carbamates, particularly, the synthesis of 1 -(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1 -(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1 -(acyloxy)-alkyl carbamates are also described.

  本文介绍了合成1-(酰氧基)-烷基氨基甲酸酯的方法，特别是合成含有一级或二级胺类药物的1-(酰氧基)-烷基氨基甲酸酯前药的方法。同时还介绍了合成1-(酰氧基)-烷基N-羟基琥珀酰亚胺碳酸酯的方法，这些化合物是合成1-(酰氧基)-烷基氨基甲酸酯的有用中间体。